https://www.thebionews.net/news/articleView.html?idxno=13113

BeyondDx Signs MOU with Luye Diagnostics for Joint Clinical Research, Marking First Step into the Chinese Market

By Kang In-hyo, The Bio | Published: 2025.02.27 06:10 | Updated: 2025.02.27 07:52

• Collaboration on clinical research for early lung cancer diagnosis and major depressive disorder (MDD) diagnostic pipelines in China
• Clinical research and development of "ForeCheck LC" for lung cancer and "ForeCheck MDD" for depression in the Chinese market

BeyondDx, a developer of multi-integrated analysis solutions, announced on the 27th that it signed a memorandum of understanding (MOU) with Beijing-based Luye Diagnostics LLC on February 7 for joint clinical research.

Under the agreement, the two companies will collaborate on local clinical research and commercialization efforts for BeyondDx’s early lung cancer diagnostic pipeline, ForeCheck LC, and its major depressive disorder diagnostic pipeline, ForeCheck MDD, in China.

Luye Diagnostics is a subsidiary of Luye Pharma Group Ltd., a leading global company specializing in oncology and neurology, headquartered in China. The company operates branches in China, Singapore, and the United States, offering genetic diagnostic reagents, companion diagnostics for cancer, and related services.

Since 2021, Luye Diagnostics has expanded its business into mental health through Mindfront Health, a subsidiary of Luye Pharma Group, providing comprehensive services from diagnosis to treatment. BeyondDx expects significant synergies with its leading diagnostic pipelines through this partnership.

China is actively investing in healthcare infrastructure under its government-led policy, "Healthy China 2030 (健康中国 2030)", which includes detailed management guidelines for chronic diseases such as cancer and mental illnesses. The initiative aims to enhance early diagnosis and treatment capabilities.

Lung cancer is a major health concern in China, with approximately 1.06 million new cases annually and one of the highest mortality rates globally, driving an urgent need for early detection solutions.

Depression is also a growing public health issue, exacerbated by psychological and social factors. Notably, 70% of suicides in China are linked to depression, yet the country faces a severe shortage of hospitals and medical professionals specializing in mental health. This highlights the urgent need for a robust early diagnosis and management system.

Jung So-jin, CEO of BeyondDx, stated, “Through our partnership with Luye Diagnostics, we aim to accelerate clinical trials, regulatory approvals, and commercialization in China, laying the groundwork for our global market expansion.”